+

WO2006043153A3 - Utilisation de chelateurs d'ions de zinc et de cuivre pour le traitement d'infections causees par des virus vehicules par le sang - Google Patents

Utilisation de chelateurs d'ions de zinc et de cuivre pour le traitement d'infections causees par des virus vehicules par le sang Download PDF

Info

Publication number
WO2006043153A3
WO2006043153A3 PCT/IB2005/003124 IB2005003124W WO2006043153A3 WO 2006043153 A3 WO2006043153 A3 WO 2006043153A3 IB 2005003124 W IB2005003124 W IB 2005003124W WO 2006043153 A3 WO2006043153 A3 WO 2006043153A3
Authority
WO
WIPO (PCT)
Prior art keywords
zinc
treatment
viral diseases
copper chelators
chelators
Prior art date
Application number
PCT/IB2005/003124
Other languages
English (en)
Other versions
WO2006043153A2 (fr
Inventor
Michel Xilinas
Original Assignee
Michel Xilinas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel Xilinas filed Critical Michel Xilinas
Publication of WO2006043153A2 publication Critical patent/WO2006043153A2/fr
Publication of WO2006043153A3 publication Critical patent/WO2006043153A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne le traitement d'infections causées par des virus véhiculés par le sang, tels que le VHC, le VHB et le VIH, au moyen d'un ou plusieurs chélateurs d'ions de zinc et/ou de cuivre.
PCT/IB2005/003124 2004-10-20 2005-10-20 Utilisation de chelateurs d'ions de zinc et de cuivre pour le traitement d'infections causees par des virus vehicules par le sang WO2006043153A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CY0400075 2004-10-20
CYCY04/00075 2004-10-20
CY0500025 2005-04-18
CYCY05/00025 2005-04-18

Publications (2)

Publication Number Publication Date
WO2006043153A2 WO2006043153A2 (fr) 2006-04-27
WO2006043153A3 true WO2006043153A3 (fr) 2006-09-14

Family

ID=36087334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003124 WO2006043153A2 (fr) 2004-10-20 2005-10-20 Utilisation de chelateurs d'ions de zinc et de cuivre pour le traitement d'infections causees par des virus vehicules par le sang

Country Status (1)

Country Link
WO (1) WO2006043153A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011073A1 (fr) * 1996-09-10 1998-03-19 Pharmacia & Upjohn Company 8-hydroxyquinoleines 7-substituees utilisees comme agents antiviraux
WO2004087160A1 (fr) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Traitement d'affections neurologiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011073A1 (fr) * 1996-09-10 1998-03-19 Pharmacia & Upjohn Company 8-hydroxyquinoleines 7-substituees utilisees comme agents antiviraux
WO2004087160A1 (fr) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Traitement d'affections neurologiques

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AGARWAL, UMA ET AL: "Effect of quinazolones, substituted hydroxyquinolines, substituted diamines, purine, and nucleoside antagonists on vaccinia virus in chick embryo", JOURNAL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, SECTION B: PHYSICAL SCIENCES , 21C, 309-12 CODEN: JSIBAW; ISSN: 0368-4210, 1962, XP008065316 *
BEDNARZ-PRASHAD A J ET AL: "EFFECT OF CLIOQUINOL AN 8 HYDROXY QUINOLINE DERIVATIVE ON ROTAVIRUS INFECTION IN MICE", JOURNAL OF INFECTIOUS DISEASES, vol. 148, no. 3, 1983, pages 613, XP008050821, ISSN: 0022-1899 *
BEDNARZ-PRASHAD J: "ALTERATION OF ROTAVIRUS INFECTIVITY AND PRODUCTION WITH CLIOQUINOL AND ACTINOMYCIN D", FEDERATION PROCEEDINGS, vol. 40, no. 6, 1981, & 72ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, ST. LOUIS, MO., USA, MAY 31-JUNE, pages 1826, XP008050820, ISSN: 0014-9446 *
LEVINSON, WARREN ET AL: "Anti-tumor virus activity of copper-binding drugs", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY , 91(INORG. NUTR. ASPECTS CANCER), 161-78 CODEN: AEMBAP; ISSN: 0065-2598, 1978, XP008065315 *
LEVINSON, WARREN ET AL: "Inactivation and inhibition of Rous sarcoma virus by copper-binding ligands: thiosemicarbazones, 8-hydroxyquinolines, and isonicotinic acid hydrazide", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES , 284, 525-32 CODEN: ANYAA9; ISSN: 0077-8923, 1977, XP008065317 *
LIEBIG, H. ET AL: "Experimental results with purposely synthetized substances for antiviral chemotherapy. 2. Further 2-amino-4-phenylthiazoles, tetrahydrobenzothiazoles, 4-phenylimidazoles, and 8-hydroxyquinolines", ARZNEIMITTEL-FORSCHUNG , 24(6), 887-92 CODEN: ARZNAD; ISSN: 0004-4172, 1974, XP008050835 *
ROHDE, WOLFGANG ET AL: "Hydroxyquinolines inhibit ribonucleic acid-dependent deoxyribonucleic acid polymerase and inactivate Rous sarcoma virus and herpes simplex virus", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , 10(2), 234-40 CODEN: AMACCQ; ISSN: 0066-4804, 1976, XP008050819 *

Also Published As

Publication number Publication date
WO2006043153A2 (fr) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2007081517A3 (fr) Composes anti-viraux
WO2007076035A3 (fr) Composes antiviraux
WO2008133753A3 (fr) Composés antiviraux
WO2001077091A3 (fr) Inhibiteurs de polymerases ns5b vhc
IL192306A0 (en) Anti-viral compounds
WO2003053344A3 (fr) 2-methyl-benzimidazole substitues en tant qu'agents antiviraux du virus respiratoire syncytial
WO2002062290A3 (fr) Agents antiviraux constitues de 2-methylbenzimidazole substitue heterocyclique
WO2004046159A8 (fr) Derives nucleosidiques antiviraux
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
WO2004071426A3 (fr) Composes destines au traitement d'une infection virale
WO2004002940A8 (fr) Inhibiteurs de la polymerase du vhc (ns5b)
WO2005063734A3 (fr) Thiophenes substitues
WO2007084413A3 (fr) Procedes de traitement de l’hepatite c
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A3 (fr) Inhibiteurs de la ns5b du vch à base d'indolobenzazépine fusionnée au cyclopropyle
WO2007140254A3 (fr) Inhibiteurs de ns5b de vhc de type indolobenzapénine fusionnée cyclopropyle
WO2006072625A3 (fr) Procedes et traitements combines anti-kir
EA200700243A1 (ru) Способы лечения гепатита с
WO2009094191A3 (fr) Méthodes de traitement d’infections virales
WO2006027628A3 (fr) Derives de naphtalimide en tant qu'agents antiviraux
WO2003055896A3 (fr) 7-deaza l-nucleosides en tant qu'antiviraux
WO2002089780A3 (fr) Composes antiviraux
WO2005084192A3 (fr) Nouveaux derives nucleosidiques de 2'-c-methyle
WO2001045712A8 (fr) Combinaison de medicaments pour lutter contre des maladies virales
WO2007002639A3 (fr) Agents anti-hepacivirus non-nucleoside et utilisations de ceux-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 08.08.2008.

122 Ep: pct application non-entry in european phase

Ref document number: 05808337

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载